Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- MHLW Submits Application for Membership in PIC/S on March 9
March 19, 2012
- PMDA to Abolish Current Rule on Re-Employment of Its Former Employees
March 16, 2012
- Integration of Advanced Healthcare Service Systems “Not Related” to Compassionate Use System: Korosho
March 16, 2012
- Bill to Amend PAL Unlikely to Be Submitted in Current Diet Session Due to Time Constraints: Health Minister Komiyama
March 15, 2012
- Korosho Begins Discussions Toward Integrating Senshin-iryo, Kohdo-iryo Systems
March 15, 2012
- Dr Sakurai of PMDA Stresses Need for Japan’s Participation in PIC/S to Create Global Inspection System
March 14, 2012
- Dissolution of Gliclazide Tablets Attributed to Large Particle Size: Generic Drug Quality Study Group
March 13, 2012
- Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
- Gov’t Releases Some Documents Related to Draft Statement on Iressa Lawsuits
March 13, 2012
- MHLW Announces Requirements for “Clinical Research Core Hospitals”
March 12, 2012
- Study Group to Discuss Whether “ABC” Screening Should Be Included in Gastric Cancer Screening: Parliamentary Secretary Fujita
March 9, 2012
- DPJ’s PAL Subcommittee to Begin Compiling Recommendations in Mid-March; Timing of Bill Unclear
March 7, 2012
- Aricept to Receive 16.7-16.8% Reduction, Lyrica 25% in Re-Pricing Due to Market Expansion
March 6, 2012
- 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
- Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
- Cancer Policy Promotion Council Submits New 5-Year Plan to Health Minister Komiyama
March 5, 2012
- Revised Ordinance Banning “Dispensing Point” Services Announced in Official Gazette
March 5, 2012
- 11 APIs/28 Products to Receive Premiums for New Pediatric, Orphan Indications
March 5, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Approval for Pfizer Japan’s ALK Inhibitor Xalkori
March 1, 2012
- MHLW Study Group Approves Outline of “Post-5-Year Plan” for Promoting Clinical Trials
March 1, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…